Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 115,056 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 115,056 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $91.01, for a total value of $10,471,246.56. Following the sale, the director owned 647,914 shares in the company, valued at $58,966,653.14. The trade was a 15.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total transaction of $24,268,431.60.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.38, for a total transaction of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.98, for a total transaction of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The stock was sold at an average price of $103.75, for a total transaction of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.08, for a total transaction of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.96, for a total value of $530,764.00.
• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.10, for a total value of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.95, for a total value of $197,890.00.
• On Tuesday, April 14th, Bruce Booth sold 4,159 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.97, for a total value of $374,185.23.

Kymera Therapeutics Stock Up 10.0%

Shares of NASDAQ:KYMR opened at $99.45 on Tuesday. Kymera Therapeutics, Inc. has a 52-week low of $36.65 and a 52-week high of $105.00. The stock has a market cap of $8.18 billion, a price-to-earnings ratio of -27.86 and a beta of 2.02. The business has a 50-day moving average price of $83.41 and a 200-day moving average price of $81.31.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. During the same quarter in the prior year, the firm earned ($0.82) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 55.5% on a year-over-year basis. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Kymera Therapeutics by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after buying an additional 1,833 shares in the last quarter. Millennium Management LLC increased its holdings in Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after buying an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after buying an additional 491,737 shares in the last quarter. Invesco Ltd. raised its position in shares of Kymera Therapeutics by 13.8% in the second quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after acquiring an additional 5,809 shares during the period. Finally, Sei Investments Co. acquired a new position in shares of Kymera Therapeutics in the second quarter worth about $265,000.

Analysts Set New Price Targets

Several brokerages recently issued reports on KYMR. Citigroup raised their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Canaccord Genuity Group assumed coverage on Kymera Therapeutics in a research report on Wednesday, May 6th. They set a “buy” rating and a $106.00 price target on the stock. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Jefferies Financial Group initiated coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $117.14.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.